Cyclic Nucleotide Phosphodiesterase Family 10 / PDE10

Introduction Cyclic nucleotide phosphodiesterases (PDEs) are enzymes hydrolyzing the second messengers adenosine and guanosine 3',5'-cyclic monophosphates (cAMP and cGMP). The human genome encodes 21 PDE genes that are categorized into 11 families. Selective inhibitors against individual PDE families have been developed as therapeutics for treatment of various human diseases. PDE10 shows a dual activity on hydrolysis of both cAMP and cGMP and is highly expressed in brain striatum. Technology description This invention provides the mouse cDNA for PDE10A and could be useful as a research tool for various projects. Several studies have described various roles for PDE10A. Reduction of PDE10A mRNA and protein levels in striatum of transgenic mice implies a role of PDE10A in Huntington's disease. Knockout mice experiments suggest that PDE10A is involved in regulating striatal output, possibly by reducing the sensitivity of medium spiny neurons to glutamatergic excitation. The PDE10 inhibitor papaverine is effective in improving executive function deficits associated with schizophrenia, and inhibition of PDE10 may represent an approach to treatment of psychosis. Related Publication(s)
Proc. Natl. Acad. Sci. USA 1999 Jun 96: 7071-7076

Type of Offer: Licensing

Next Patent »
« More Biomedical Patents

Share on      

CrowdSell Your Patent